Simultaneous determination of five active alkaloids from Compound Kushen Injection in rat plasma by LC–MS/MS and its application to a comparative pharmacokinetic study in normal and NSCLC nude rats

Published on Sep 1, 2019in Journal of Chromatography B2.81
· DOI :10.1016/j.jchromb.2019.121734
Song Cang (SPU: Shenyang Pharmaceutical University), Ran Liu10
Estimated H-index: 10
(SPU: Shenyang Pharmaceutical University)
+ 4 AuthorsQing Li22
Estimated H-index: 22
(SPU: Shenyang Pharmaceutical University)
Abstract Non-small cell lung cancer (NSCLC), as the most common histological type of lung cancer with high mortality rates, has been widely treated by Compound Kushen Injection (CKI) in China. Among various active components with many pharmacologic properties, matrine, oxymatrine, sophoridine, oxysophocarpine and N-methylcytisine, are the main bioactive alkaloids of CKI. Therefore, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to simultaneously quantify the five alkaloids in nude rat plasma in this study. With aminopyrine as internal standard (IS), plasma samples were extracted by alkalified chloroform and then separated on an Agela Venusil MP C18 column (2.1 mm × 100 mm, 3 μm) using gradient elution. Water containing 10 mmol/L ammonium acetate (adjusted to pH 8.0 with ammonia water, A) and methanol (B) constituted the mobile phase system. Notably, the analysis was rapid and accurate due to a short running time of 6 min and a stereoisomer separation between matrine and sophoridine. Detection was implemented in MRM mode with an electrospray positive ionization source. Validation parameters were all in accordance with current criterion. The established method has been effectively employed to compare the pharmacokinetic behaviors of five alkaloids between normal and NSCLC nude rats. Results indicated that the pharmacokinetic behaviors of oxymatrine, sophoridine and N-methylcytisine from CKI could be changed when it was intravenously administrated to the NSCLC model rats, and possible reasons have been proposed. This study could provide meaningful reference for further clinical medication of CKI when combined with time-effect curve and clinical symptoms.
  • References (32)
  • Citations (0)
#1Freddie Ian Bray (IARC: International Agency for Research on Cancer)H-Index: 88
#2Jacques Ferlay (IARC: International Agency for Research on Cancer)H-Index: 66
Last.Ahmedin Jemal (ACS: American Cancer Society)H-Index: 106
view all 6 authors...
#1Wei LiH-Index: 44
#2Xinfang Yu (Cleveland Clinic)H-Index: 3
Last.Haidan Liu (CSU: Central South University)H-Index: 13
view all 6 authors...
#1Jie Wu (SJTU: Shanghai Jiao Tong University)H-Index: 6
#2Yan Cai (SEU: Southeast University)H-Index: 4
Last.Zhujun Tan (SJTU: Shanghai Jiao Tong University)H-Index: 16
view all 6 authors...
#1Zhenbao Li (SPU: Shenyang Pharmaceutical University)H-Index: 8
#2Lei Shang (PRC: China Medical University (PRC))H-Index: 1
Last.Jin Sun (SPU: Shenyang Pharmaceutical University)H-Index: 30
view all 10 authors...
Cited By0
View next paperPharmacokinetic study of multiple active constituents from Kushen–Gancao Decoction after oral administration in rat by HPLC–MS/MS